Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin and RAD001 in Advanced Neuroendocrine Carcinoma
NCT00607113Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2008
- Primary completion
- Oct 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in neuroendocrine carcinoma (NEC) comparing Avastin First with RAD001 First (2 arms). Primary endpoint: Net Change Relative to Baseline in Tumor Blood Flow at Day 63. Started Jan 2008; status: completed.
02
Drugs
bevacizumabeverolimus
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT00607113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607113.